Marie Skłodowska-Curie Action
Innovative Training Networks (ITN)

2015-2019

 

Funded by

marie curie actions   Marie Curie Actions

 

 

unnamed   
EU Horizon 2020

 

 

european union logo   European Union

 

Genetic mouse models and in vivo studies

Early stage researcher 14 (ESR14) project

Supervision: Prof S Offermanns, Dr N Wettschureck, Dr S Tunaru, Dr A Sassmann, Dr S Tonack

Host: MPG (DE) – Max Planck Institute for Heart and Lung Research, Dept. of Pharmacology I- Project proposal:



Aim:

1. Generation of mouse lines expressing mutated GPCRs with altered pharmacological and signalling properties.

2. Analysis of GPCR expression level and localization using transgenic/genetic approaches.

3. Phenotyping mice with mutated GPCRs for pharmacological and signalling properties.

4. Evaluation of GPCR modulators in in vivo heterotopic xenograft model systems.



Methodology:
BAC (Bacterial Artificial Chromosome) transgenics, constitutive and conditional mutagenesis, tumor growth and metastasis studies, calorimetry, insulin/glucose tolerance assay, ex vivo study of mitochondria function.

Planned secondments: INSERM (FR), UGL (UK).



II- Requirement candidate:

Required diploma: MSc degree in molecular / biomedical life sciences

Required expertise: molecular biology, genetics, biochemistry

Recommended expertise: animal handling and experimentation, imaging



Key publications:
1. Tang C, Ahmed K, Gille A, Lu S, Gröne HJ, Tunaru S, Offermanns S (2015) Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat. Med. 21, 173.

2. Offermanns S (2014) Free Fatty Acid (FFA) and Hydroxy Carboxylic Acid (HCA) Receptors. Annu. Rev. Pharmacol. Toxicol. 54, 407.

3. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S (2013) Platelet-derived nucleoides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24, 130.

4. Blad CC, Tang C, Offermanns S (2012) G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discov. 11, 603.

Lijndik